Governance for approving AI recommendations in critical investigations


Governance for Approving AI Recommendations in Critical Investigations

Published on 05/12/2025

Governance for Approving AI Recommendations in Critical Investigations

As artificial intelligence (AI) increasingly permeates the pharmaceutical and biotechnology sectors, understanding governance surrounding AI-enabled deviation investigations becomes crucial for regulatory affairs professionals. This article provides a structured explanation of relevant regulations, guidelines, and expectations associated with AI in quality systems, focusing on the governance for approving AI recommendations in critical investigations.

Context

The integration of AI technology, especially machine learning (ML) models, into quality management systems (QMS) is transforming deviation investigations, root cause analysis, and deviation triage. AI’s ability to process vast amounts of data allows for efficiency and accuracy, but it also raises significant governance challenges. Regulatory bodies like the FDA, EMA, and MHRA mandate robust frameworks to ensure the reliability of AI-driven processes and decisions.

Legal/Regulatory Basis

The foundation for the governance of AI in regulatory contexts is established by several key documents and regulations:

  • 21 CFR Part 11: This regulation outlines the criteria under which electronic records and electronic signatures are considered trustworthy, reliable, and equivalent to traditional paper records and handwritten signatures.
  • EU Regulation No. 536/2014: This regulation governs clinical trials in the EU, emphasizing good clinical practice (GCP) and data integrity.
  • ICH Guidelines:
Various guidelines, especially ICH E6(R2), provide principles for GCP, which apply to data management processes incorporating AI.
  • ISO 9001:2015: This standard sets requirements for a QMS, ensuring that organizations consistently provide products that meet customer and regulatory requirements, making it applicable in the context of AI in quality systems.
  • Documentation

    Effective documentation practices are essential for AI-enabled deviation investigations. The following elements must be meticulously documented:

    Data Integrity and Provenance

    Documenting the integrity of data inputs and outputs from ML models is vital. Ensure that records reflect:

    • Source of data, including any transformations applied.
    • Versioning of datasets and models used.
    • Validation steps undertaken for the ML model.

    Model Governance

    Establish a framework to document:

    • Assumptions made during model development.
    • Baseline performance metrics.
    • Periodic assessments post-implementation to verify ongoing effectiveness.

    Decision Rationale

    It is crucial to document the justification for utilizing AI recommendations in deviation investigations. This includes:

    • Reference to historical data supporting the decision to rely on AI.
    • Explanation of traditional methods versus AI-driven insights.
    • Clear identification of stakeholders involved in the decision-making process.

    Review/Approval Flow

    Implementing a structured review and approval flow is necessary to govern AI recommendations effectively. The typical flow includes:

    Initial Assessment

    Upon identification of a deviation, a preliminary assessment should involve:

    • Human verification of the deviation data.
    • Initial classification of the deviation type.
    • Determination of whether AI intervention is appropriate.

    AI Triage

    The triage process should utilize AI models appropriately, followed by:

    • Cross-validation with historical data and outcomes from past investigations.
    • Human review of AI-generated insights, ensuring no critical factors are overlooked.

    Collaboration with Quality Assurance

    Collaborate with the QA team to finalize documented findings. Ensure that:

    • QA representatives review all AI recommendations before acceptance.
    • Documentation of any alternative investigation routes taken if AI suggestions are not applied.

    Common Deficiencies

    Despite advancements in AI, several common deficiencies can hinder effective governance in deviation investigations. Awareness of these pitfalls can facilitate better compliance and avoid regulatory scrutiny.

    Lack of Transparency

    Regulatory bodies are vigilant about understanding AI decision pathways. Deficiencies often stem from:

    • Insufficient documentation regarding the model’s decision-making process.
    • Failure to identify and communicate the data sources used for training the AI model.

    Inadequate Data Quality Control

    Relying on poor quality data can lead to erroneous conclusions. Address deficiencies by ensuring:

    • Regular audits of datasets used for training models.
    • Comprehensive checks performed prior to using data in investigations.

    Neglecting Human Oversight

    A prevalent deficiency arises when organizations overlook the necessity of human intervention. Address this by:

    • Ensuring a clear chain of accountability for AI decisions.
    • Establishing protocols for human review at critical decision points.

    Practical Tips for Documentation and Justification

    Ensuring robust governance in AI-enabled investigations necessitates attention to detail in documentation and justifications. Here are practical tips for regulatory professionals:

    Implement a Standard Operating Procedure (SOP)

    Develop detailed SOPs outlining:

    • The workflow for documenting AI-related investigations.
    • The steps required for validating AI recommendations.

    Utilize Change Control Processes

    Establish a change control process to manage updates in AI models and ensure:

    • Consistent re-evaluation of model performance with new data.
    • Formal documentation of any significant changes made to the AI model.

    Engage Cross-Functional Teams

    Foster collaboration between departments, including:

    • Regulatory affairs to ensure compliance understanding.
    • Quality control and assurance to maintain high standards.
    • IT teams to ensure data integrity and technology support.

    Conclusion

    Governance surrounding AI recommendations in critical investigations requires a comprehensive understanding of regulatory expectations and a commitment to quality standards. By following established guidelines and maintaining rigorous documentation practices, organizations can effectively integrate AI into their QMS while minimizing regulatory risks. For further details, the EU Clinical Trials Regulation can be found at this link, providing deep insights into maintaining compliance in clinical settings.

    See also  Common pitfalls in metric based risk ranking and how to avoid bias